RxDoctor Payments DataLook up a doctor →

John Lantis, MD

Vascular Surgery · New York, NYNPI 1689663759

Payments from drug & device makers

$1,442,934in general payments, 2019–2025

Across 837 payments — averaging $1723.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$418K
  • Kerecis Limited$359K
  • Smith+Nephew$219K
  • Integra Lifesciences Corporation$205K
  • Organogenesis Inc.$84K
  • Solventum Corporation$31K
  • plus $127K from 36 others
$8,200in research payments, 2019–2025

Across 5 payments — averaging $1640.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Integra Lifesciences Corporation$5K
  • Kerecis Limited$3K
  • Biotissue Holdings Inc.$1K

What the payments were for

  • Royalty or licence$1,8610%
  • Consulting fees$490,59053%
  • Speaking & faculty fees$275,79130%
  • Travel & lodging$139,73415%
  • Food & beverage$11,9711%
  • Education$2,4280%
  • Gifts$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,442,934 in reported general payments places this provider in the 95th percentile of 405 vascular surgery providers in New York.

See all vascular surgery providers in New York

Medicare billing

Part B allowed, 2024
$287,404
Medicare patients
340
Services billed
4,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.53$32,716
Triamcinolone Acetonide62$1,807
Cilostazol30$438
Ammonium Lactate16$375
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$163
Oxycodone Hcl20$130
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$84
Gabapentin12$67
Tramadol Hcl11$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$218,740$32,71653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 405 vascular surgery providers in New York.

Other vascular surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →